Pershing Square investment in Allergan & Valeant in 2014

Pershing Square invested in Allergan & Valeant in 2014 and made public a presentation for it. If you are interested to learn about how hedge funds write presentations, here is one for you to learn from.

About the Pershing Square deck

All information is public information (I won’t share anything confidential on this site).

About the deal

In 2014, Pershing Square Capital Management, led by Bill Ackman, made a significant investment in the pharmaceutical sector by partnering with Valeant Pharmaceuticals in an attempt to acquire Allergan, the maker of Botox. This strategic move was notable not just for its ambition but also for the unconventional approach of a hedge fund collaborating directly with a company to pursue a takeover of another company.

Pershing Square built a substantial position in Allergan shares, becoming one of its largest shareholders. The strategy was to support Valeant in its bid to take over Allergan, a move that if successful, would create a global pharmaceutical giant. The partnership between Pershing Square and Valeant aimed to leverage Valeant’s aggressive acquisition strategy, which had significantly expanded its portfolio of pharmaceutical products and companies over the years.

The bid for Allergan was highly publicized and became contentious. Allergan resisted the takeover attempt, leading to a protracted battle involving lawsuits, public statements, and appeals directly to shareholders. Allergan’s defense strategies included seeking white knight companies and exploring other strategic alternatives to increase shareholder value and fend off Valeant’s advances.

Ultimately, the takeover bid for Allergan by Valeant, backed by Pershing Square, was unsuccessful. Allergan escaped the takeover by agreeing to be acquired by Actavis (later known as Allergan, plc after the acquisition), another pharmaceutical company, in a deal more favorable to Allergan’s interests and arguably more palatable to its shareholders.

The Valeant-Pershing Square attempt to acquire Allergan ended with Pershing Square making a substantial profit from its investment in Allergan, thanks to the increase in Allergan’s stock price driven by the acquisition battle. However, the episode also raised questions about the ethics and legality of hedge funds directly partnering with companies to pursue takeovers, leading to regulatory scrutiny and legal challenges. The aftermath saw Valeant’s business practices and acquisition-driven growth model come under heavy criticism, leading to a significant decline in its market value.

About Pershing Square Capital

Pershing Square Capital Management, founded by Bill Ackman in 2004, is a New York-based hedge fund known for its activist investment strategy. The fund specializes in taking significant positions in large-cap companies, with the intent of influencing management and the board to implement changes that enhance shareholder value. Pershing Square’s approach often involves advocating for strategic shifts, operational improvements, and financial restructuring. The fund’s portfolio is concentrated, typically comprising a select group of investments that Ackman and his team rigorously research and believe to be undervalued or underperforming relative to their potential.

Over the years, Pershing Square has engaged in several high-profile activist campaigns, some of which have been markedly successful, while others have attracted controversy and debate within the investment community. The fund’s notable investments include stakes in companies across various industries, from retail and fast food to pharmaceuticals and financial services. Despite the mixed outcomes of some campaigns, Pershing Square has maintained a significant influence in the hedge fund industry, underscored by Ackman’s reputation as a strategic thinker and a tenacious advocate for value creation. The fund’s performance has seen fluctuations, reflecting the inherent risks of activist investing and the volatility of the markets, but it continues to attract attention for its bold strategies and its impact on the companies it targets.

About Allergan & Valeant

Allergan, headquartered in Dublin, Ireland, and Valeant Pharmaceuticals International, Inc., now known as Bausch Health Companies Inc., are two prominent pharmaceutical companies with diverse portfolios in the healthcare industry. Allergan specializes in pharmaceuticals, focusing on ophthalmology, neurology, medical aesthetics, and dermatology, with notable products such as Botox. Valeant Pharmaceuticals, based in Laval, Quebec, Canada, operates in specialty pharmaceuticals, offering a range of branded and generic pharmaceuticals, OTC drugs, and medical devices across various therapeutic areas. Despite their individual strengths and market positions, both companies have experienced significant corporate developments, mergers, and legal challenges that have shaped their operations and market presence. Nonetheless, they continue to play vital roles in providing innovative treatments and solutions to patients globally, contributing to advancements in healthcare and pharmaceuticals.

Want to see more?

Head here to see the rest of the collection:

Hedge Fund Presentations